Brii Biosciences Revenue

In the year 2024, Brii Biosciences had annual revenue of 49.94M CNY, down -10.65%. Brii Biosciences had revenue of 27.78M in the half year ending December 31, 2024, a decrease of -70.57%.

Revenue

49.94M CNY

Revenue Growth

-10.65%

P/S Ratio

23.84

Revenue / Employee

509.55K CNY

Employees

Market Cap

163.11M USD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	49.94M	-5.96M	-10.65%
Dec 31, 2023	55.89M	-66.39M	-54.29%
Dec 31, 2022	122.28M	29.74M	32.13%
Dec 31, 2021	92.54M	10.32M	12.56%
Dec 31, 2020	82.22M	62.02M	307.10%
Dec 31, 2019	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Endo, Inc.	1.73B
Veradigm	588.02M
Tian'an Technology Group	1.78M
Elite Pharmaceuticals	84.04M
Glass House Brands	215.62M
American Oncology Network	1.76B
Northwest Biotherapeutics	1.47M
Silence Therapeutics	27.70M

Revenue Rankings

Brii Biosciences News

2 months ago - Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss - PRNewsWire
3 months ago - Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification - PRNewsWire
6 months ago - Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study - PRNewsWire
8 months ago - Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA - PRNewsWire
1 year ago - Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 - PRNewsWire
1 year ago - Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer - PRNewsWire
1 year ago - Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023 - PRNewsWire
2 years ago - Brii Biosciences Provides Latest Clinical Development and Corporate Updates - PRNewsWire

More News